Angiotensinogen promoter methylation predicts bevacizumab treatment response of patients with recurrent glioblastoma.

ABSTRACT: Patients with recurrent glioblastoma achieving response to bevacizumab combined with chemotherapy have clinical improvement and prolonged survival. High gene expression of angiotensinogen (AGT) is associated with a poor bevacizumab response. Because AGT expression is epigenetically regulated, we aimed to investigate whether AGT promoter methylation in tumor tissue predicts response to bevacizumab combination therapy in patients with recurrent glioblastoma. The study included 159 patients with recurrent glioblastoma, treated with bevacizumab combination treatment (training cohort, n = 77; validation cohort, n = 82). All patients could be evaluated for treatment response and biomarkers. DNA methylation of 4 CpG sites in the AGT promoter was measured using pyrosequencing. A model for nonrespo

SUBMITTER: Urup T 

PROVIDER: S-EPMC7191184 | biostudies-literature | 2020 May

REPOSITORIES: biostudies-literature